TMEM10 Inhibitors
Chemical inhibitors of TMEM10 can modulate its function through various intracellular signaling pathways. Wortmannin and LY294002, both phosphoinositide 3-kinase (PI3K) inhibitors, can alter the activity of TMEM10 by disrupting the PI3K signaling cascade, which is crucial for numerous cellular processes, including those involving TMEM10. The functional inhibition of TMEM10 may arise due to impaired cellular localization or activity when PI3K is inhibited. Other inhibitors, such as PD98059 and U0126, target the mitogen-activated protein kinase (MAPK/ERK) pathway, which can interact with TMEM10-related cellular mechanisms. PD98059 acts by inhibiting MAPK/ERK, leading to decreased phosphorylation and activation of proteins associated with TMEM10's function, while U0126 selectively inhibits MEK1/2, upstream regulators of the ERK pathway, dampening the pathway's influence on TMEM10.
In addition, inhibitors like SB203580 and SP600125, which target different components of the MAPK pathway, can impact TMEM10's activity. SB203580 inhibits p38 MAP kinase, potentially interfering with TMEM10 functions if they are modulated by stress-activated signaling pathways. Conversely, SP600125 inhibits c-Jun N-terminal kinase (JNK), and if TMEM10 relies on JNK-dependent signaling, its activity can be diminished by this inhibitor. Src family kinases, involved in various signaling pathways, can be inhibited by PP2 and Dasatinib. TMEM10, if it operates in conjunction with Src kinase signaling, can experience functional inhibition due to the disruption of these pathways. Y-27632, a ROCK inhibitor, can affect TMEM10 by altering the Rho-associated protein kinase pathways that might control TMEM10's cellular localization and function. Moreover, inhibitors like Gefitinib and Dasatinib, which target tyrosine kinases such as the epidermal growth factor receptor (EGFR) and Src family kinases, can influence TMEM10 activity by disrupting signaling pathways that interact with these kinases. Lastly, Bortezomib, a proteasome inhibitor, can affect TMEM10 by preventing the normal degradation of proteins involved in TMEM10's regulatory pathways, leading to altered TMEM10 activity due to the accumulation of these proteins.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3K), and since TMEM10 is known to be involved in cellular processes that are regulated by PI3K signaling, inhibiting PI3K can lead to a functional inhibition of TMEM10 by preventing its proper localization or function within the cell membrane processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor. By inhibiting PI3K, it can disrupt downstream signaling pathways essential for the function and regulation of TMEM10, leading to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of the mitogen-activated protein kinase (MAPK/ERK) pathway, which interacts with cellular pathways involving TMEM10. Inhibition of MAPK/ERK can reduce the phosphorylation and activation of proteins that may be required for TMEM10's function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 selectively inhibits MEK1/2, which are upstream regulators of the ERK pathway. As the ERK pathway can influence the function of TMEM10, inhibition by U0126 can lead to reduced functional activity of TMEM10. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, part of the MAPK pathway. By inhibiting p38, it can interfere with the function of TMEM10, particularly if TMEM10's activity is modulated by stress-activated signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK pathway. If TMEM10 function is JNK-dependent, inhibition by SP600125 can lead to functional inhibition of TMEM10. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor. If TMEM10 functions are associated with Src kinase signaling, PP2 can inhibit these signaling pathways, thus functionally inhibiting TMEM10. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor and since Rho-associated protein kinase (ROCK) pathways can modulate the cellular localization and function of transmembrane proteins like TMEM10, its inhibition by Y-27632 can result in the functional inhibition of TMEM10. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which may interact with signaling pathways involving TMEM10. By inhibiting EGFR, Gefitinib can lead to functional inhibition of TMEM10 through these pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, known to inhibit Src family kinases. If TMEM10's function is influenced by Src kinase activity, then Dasatinib can functionally inhibit TMEM10 through this mechanism. | ||||||